Tag Archives: acute coronary syndrome

doble antiagregacion plaquetaria sexo

Optimal Intervention Timing for NSTEMI with No Antiaggregant Pre-Treatment

Optimal Intervention Timing for NSTEMI with No Antiaggregant Pre-Treatment

Patients undergoing non-ST elevation MI (NSTEMI) who are not pre-treated with P2Y12 receptor inhibitors will benefit from a very early intervention strategy.  The optimal intervention timing for NSTEMI patients is still under debate, despite multiple studies, but the ideal timing had never been tested in patients with no platelet aggregation inhibitor pretreatment.  After the surge of

Manejo de los infartos durante la pandemia de Covid-19

Temporary Emergency Guidelines for Infarction During the Pandemic

Several United States societies (the American Heart Association [AHA] among them) have answered the question of many physicians in the front lines: what is the ideal strategy for the treatment of ST segment elevation myocardial infarction (STEMI) during the COVID-19 pandemic? This document intends to ensure that patients with STEMI continue to receive adequate, proven

ACC Virtual 2020 | TICO: monoterapia de ticagrelor en síndromes coronarios agudos

Virtual ACC 2020 | TICO: Ticagrelor Monotherapy in Acute Coronary Syndromes

Switching to ticagrelor monotherapy after 3 months of dual antiplatelet therapy reduces major bleeding without paying a price in terms of ischemic events, compared with dual antiplatelet therapy for a year, in patients who had acute coronary syndrome and underwent angioplasty with a second-generation drug-eluting stent. Interrupting aspirin at 3 months and switching it for ticagrelor reduces

AHA 2019 | TWILIGHT: discontinuar la aspirina luego de un síndrome coronario agudo

AHA 2019 | TWILIGHT: Discontinue Aspirin after Acute Coronary Syndrome

This study findings confirm less bleeding at no extra cost of thrombotic events when aspirin is discontinued after an acute coronary syndrome (ACS).  In the same line as the original TWILIGHT, this study focused on ACS patients alone (excluding STEMI) and confirmed that aspirin discontinuation after 3-month DAPT to continue with ticagrelor alone, reduced the

REVELATION: Balones liberadores de droga en infartos con supradesnivel del segmento ST

EuroPCR 2019 | REVELATION: Drug Coated Balloons in ST Elevation MI

Drug coated balloons in the context of ST elevation acute myocardial infarction seem safe and feasible under certain circumstances. This single center study is the kickoff to keep studying the possibility of “leaving nothing behind” after primary PCI. This small randomized study revives drug coated balloons to be used particularly instead of stents in young

PCI Right After CABG: How Bad Can it Be?

In-hospital PCI right after CABG is extremely rare, but it does increase morbidity, mortality and costs significantly. It is still unclear what predictors can be modified to prevent these very early angiography and angioplasty procedures in patients that generally leave the OR with visible EKG changes. Graft failure, distal vascular bed quality, technical error or

Optimal Revascularization Time in Transient STEMI

Patients admitted with transient ST elevation MI and later normalize completely (symptimos disappear before being treated) are those we normally say are “undergoing a non-ST elevation MI”. This is complex, because revascularization time remains nuclear, as is whether to treat them as STEMI or non-STEMI patients. The aim of this study was to determine the

Cortar las valvas, una medida extrema para evitar la oclusión coronaria post TAVI

Acute Coronary Syndromes After TAVR: Frequent and Not All Undergo Coronary Angiography

Approximately 10% of patients who undergo transcatheter aortic valve replacement (TAVR) are readmitted for an acute coronary syndrome after a mean follow-up of 25 months. Male sex, prior coronary artery disease, and (surprisingly and hard to explain) nontransfemoral approach were independent predictors of acute coronary syndrome after TAVR, an event associated with high midterm mortality. While

Can We Discontinue Betablockers after AMI?

Betablockers (BB) were the first drugs shown to effectively reduce events after acute MI. However, reperfusion and other secondary prevention drugs that came along after that have cast a shadow on betablockers’ original benefit. This study looked at betablocker discontinuation after acute MI in patients with no cardiac failure optimally treated with all recommended medication.

Top